CNMD Financials Conmed Corp

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Oct 31, 2026, 11:16 UTC Overview →

Growth & profitability

Revenue has grown 9.8% per year over the past 5 years.
Net income has grown faster than revenue (37.7% vs 9.8% per year).
Operating margin has expanded, at 7.5% in the latest year.
Free cash flow has grown 24.0% per year over the past 5 years.

Financial health

Total debt has grown faster than revenue (16.2% vs 9.8% per year).
Operating income covered interest expense 3.3× in the latest year, up from 1.0× 5 years ago.

Shareholder returns

Dividends have been paid for 14 consecutive years, consuming 52.5% of earnings and 16.4% of free cash flow.
The dividend has grown 1.6% per year over the past 5 years.

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Return on equity & assets (ROE / ROA)

ROEROA

Free cash flow (CFO − capex)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key annual figures

FY	Revenue	Net income	Gross M	Op M	ROE	ROA	FCF	Total debt	Cash
2025	$1.4B	$47M	54.6%	7.5%	4.6%	2.0%	$151M	—	$41M
2024	$1.3B	$132M	56.1%	15.3%	13.8%	5.7%	$154M	—	$24M
2023	$1.2B	$65M	54.3%	9.7%	7.7%	2.8%	$106M	—	$24M
2022	$1.0B	-$81M	54.6%	6.7%	-10.8%	-3.5%	$12M	—	$29M
2021	$1.0B	$63M	56.2%	10.9%	8.0%	3.5%	$97M	—	$21M
2020	$862M	$10M	53.4%	5.3%	1.3%	0.5%	$52M	—	$27M
2019	$955M	$29M	54.9%	8.3%	4.0%	1.6%	$75M	—	$26M
2018	$860M	$41M	54.6%	8.3%	6.2%	3.0%	$58M	$457M	$18M
2017	$796M	$55M	54.1%	5.9%	8.8%	4.1%	$53M	$486M	$33M
2016	$764M	$15M	53.5%	4.9%	2.5%	1.1%	$25M	$498M	—
2015	—	$30M	—	—	5.2%	2.8%	$36M	$271M	—
2014	—	$32M	—	—	5.5%	2.9%	$50M	$241M	—
2013	—	$36M	—	—	5.9%	3.3%	$63M	$216M	—
2012	—	$40M	—	—	6.7%	3.8%	$74M	$162M	—
2011	—	$752000	—	—	0.1%	0.1%	$85M	$144M	—

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Return on equity & assets (ROE / ROA)

ROEROA

Free cash flow (CFO − capex, quarterly)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key quarterly figures

Quarter	Revenue	Net income	Gross M	Op M	ROE	ROA	FCF	Total debt	Cash
Sep '26	$336M	$20M	56.4%	11.1%	1.9%	0.9%	$47M	—	$48M
Jun '26	$343M	$23M	57.5%	10.6%	2.2%	1.0%	—	—	$37M
Dec '25	$373M	$17M	58.5%	9.8%	1.6%	0.7%	$41M	—	$41M
Sep '25	$338M	$3M	49.2%	3.5%	0.3%	0.1%	$48M	—	$39M
Jun '25	$342M	$21M	55.0%	11.1%	2.1%	0.9%	$23M	—	$34M
Mar '25	$321M	$6M	55.3%	5.0%	0.6%	0.3%	$38M	—	$35M
Dec '24	$346M	$34M	57.3%	15.2%	3.5%	1.5%	$39M	—	$24M
Sep '24	$317M	$49M	56.5%	20.7%	5.3%	2.1%	$48M	—	$38M
Jun '24	$332M	$30M	55.3%	14.2%	3.4%	1.3%	$40M	—	$29M
Mar '24	$312M	$20M	55.1%	11.2%	2.3%	0.9%	$27M	—	$34M
Dec '23	$327M	$33M	55.7%	15.3%	4.0%	1.4%	$52M	—	$24M
Sep '23	$305M	$16M	55.2%	9.9%	2.0%	0.7%	$41M	—	$31M
Jun '23	$318M	$14M	53.7%	8.6%	1.8%	0.6%	$22M	—	$28M
Mar '23	$295M	$2M	52.6%	4.3%	0.2%	0.1%	-$8M	—	$26M
Dec '22	$251M	$27M	52.6%	-0.4%	3.6%	1.2%	-$17M	—	$29M
Sep '22	$275M	$46M	55.1%	8.8%	6.4%	2.0%	$19M	—	$33M
Jun '22	$277M	-$168M	54.8%	8.8%	-25.0%	-8.1%	$13M	—	$53M
Mar '22	$242M	$15M	56.1%	9.3%	1.9%	0.8%	-$3M	—	$25M
Dec '21	$274M	$24M	56.9%	13.6%	3.1%	1.4%	$31M	—	$21M
Sep '21	$249M	$15M	57.2%	10.7%	2.0%	0.9%	$16M	—	$32M

Valuation over time

How the market has priced CNMD against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

The price-to-earnings ratio has fallen from 41.2× (Jan '24) to 29.5× (Nov '26).
The price-to-sales ratio has fallen from 3.0× (Mar '23) to 1.0× (Nov '26).
The dividend yield has risen from 0.8% (Mar '23) to 1.8% (Nov '26).

Price / earnings (P/E)

P/E

Price / sales (P/S)

P/S

Dividend yield (%)

Dividend yield %

Frequently asked questions

Is CNMD growing its revenue and profit?

Over the past 5 years, Conmed Corp's revenue has grown 9.8% per year, and net income grown 37.7% per year. These are computed facts, not advice.

How much debt does CNMD have?

As of FY2025, Conmed Corp reported — of total debt against $41M of cash; operating income covered interest expense 3.3×.

What is CNMD's profit margin?

In FY2025, gross margin was 54.6%, operating margin 7.5%, and net margin 3.4%.

What is CNMD's P/E ratio?

Conmed Corp's P/E (TTM) is 29.48 as of the 2026-11-02 close — market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year, the same figure as on the CNMD stock page. The valuation chart above sets each month-end's price against the latest annual net income instead, so its latest point (about 29.5× as of Nov '26) can differ. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.